EdiGene will showcase getools, a data analysis software toolkit for advanced analysis of DNA and RNA editing efficiency and results for therapeutic development at the 25th Annual Meeting of the ASGCT

BEIJING AND CAMBRIDGE, Mass.–(BUSINESS WIRE)–BEIJING and CAMBRIDGE, MASS. – (May 2, 2022) – EdiGene, Inc., a global clinical-stage biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, will present geotools (gene editing data analysis toolkit) for the advanced analysis of DNA and RNA editing efficiency and results for therapeutic development at the annual meeting of the American Society of Gene & Cell Therapy (ASGCT) May 16-19, 2022 in Washington, DC

Powered by an in-house developed algorithm framework, geotools enables more efficient and accurate analysis of the complex mixed mutational spectrum in vitro and live, in bulk or at the single-cell level, of the efficiency and results of DNA and RNA editing compared to other existing analytical tools. It provides data security with localized deployment and provides industry-standard reports and result files of various formats for full-cycle data tracing and workflow integration. These characteristics contribute to gene editing studies, from laboratory research to therapeutic development.

Presentation details:

Title:
geotools Enables ultra-fast and accurate quantification of gene-editing results with bulk and single-cell data from genome-editing experiments

Session Date/Time: Wednesday, May 18, 2022 5:30 p.m. – 6:30 p.m.

Session title: Gene Targeting and Gene Correction III

Abstract number: 962

“The development of geotools demonstrates our expertise in gene editing and bioinformatics and our ability to leverage them to create solutions and provide insights for therapeutic development,” said Dong Wei, Ph.D., CEO of EdiGene. “Innovative gene-editing therapies are beginning to show their breakthrough potential, and for such a new therapeutic modality, new tools and analytics are needed to quantitatively analyze and monitor the results of gene-editing at the acid level. to determine the risks and benefits of a therapeutic candidate.EdiGene is dedicated to advancing this innovation to facilitate the development of DNA and RNA editing-based therapies for patients in need.

EdiGene has established three centers of excellence with underlying gene editing, bioinformatics and high throughput genome editing screening technologies. This scientific expertise and capabilities are integrated into the entire therapeutic development process through its four gene-editing therapeutic platforms for ex-vivo, in-vivoand targeted therapies.

About EdiGene, Inc.

EdiGene is a global clinical-stage biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer. The company has established its sole ownership ex-vivo genomic editing platforms for hematopoietic stem cells and T lymphocytes, live therapeutic platform based on RNA base editing and high throughput genome editing screening to discover novel targeted therapies. Founded in 2015, EdiGene is headquartered in Beijing, with offices in Guangzhou and Shanghai, China, and Cambridge, Massachusetts, USA. More information can be found at www.EdiGene.com.

Comments are closed.